Eli Lilly disclosed top‑line results from a phase III trial showing retatrutide, a triple agonist targeting GLP‑1, GIP and glucagon receptors, produced substantial glycemic control and weight loss in type 2 diabetes. In Transcend‑T2D‑1 the drug cut HbA1c by up to ~1.9 percentage points and patients on the highest dose lost an average of 36.6 pounds at 40 weeks, the company reported. The lead sentence: retatrutide met its primary and key secondary endpoints with marked A1C reductions and unprecedented weight loss for a T2D population. Investigators and external experts cited the magnitude of weight loss and A1C lowering as notable compared with prior agents; safety signals were consistent with incretin‑class effects (nausea, diarrhea). Analysts flagged the need to see full data and peer‑reviewed publication to evaluate durability, subgroups and safety. The trial used standard randomized, placebo‑controlled design and enrolled patients with mean disease duration of ~2.5 years. Regulators and payers will watch tolerability, cardiovascular outcomes and how the new agent positions against approved GLP‑1 and dual‑agonists. Retatrutide’s results accelerate the race among large pharma for next‑generation metabolic medicines and will drive decisions on regulatory filings and commercial strategy.